Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-06-05
1998-03-17
Reamer, James H.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31365
Patent
active
057287260
ABSTRACT:
A method for selectively inhibiting a kinase is disclosed, which comprises contacting a composition containing a kinase with a molecule of the formula ##STR1## wherein R.sub.1 is H, lower alkyl, or lower alkanoyl; R.sub.2 is H, lower alkyl, or lower alkanoyl; R.sub.3 and R.sub.4 together represent a cis double bond or --0-- or each of R.sub.3 and R.sub.4 independently represents H or OR; R.sub.5 is .dbd.O, .dbd.S, or --H, --OR; R.sub.6 and R.sub.7 together represent a double bond or --O-- or each of R.sub.6 and R.sub.7 independently represents H or OR; R.sub.8 and R.sub.9 together represent a double bond or --O-- or each of R.sub.8 and R.sub.9 independently represents H or OR; and each R independently represents H, lower alkyl, or lower alkanoyl.
REFERENCES:
Arch. Geschwulstforsch., vol. 53, No. 1, 1983, pp. 9-15, XP000568651, R. Thust et al.: "Genotoxicity of Fusarium mycotoxins (nivalenol, fusarenon-x, t-2 toxin and zearalenone) in Chinese hamster V79-E cells in vitro".
Proc. Annu. Meet. Am. Assoc. Cancer Res., vol. 35, 1994, p. 88, XP002001543, D. T. Zava et al.: "Effects of plant and fungal estrogens on E-sensitive human breast cancer cells." abstract #525.
Cell, vol. 69, No. 7, 1992, pp. 1227-1236, XP000567055, J. Chung et al.: "Rapamycin-FKBP specifically blocks growth-dependent activation of and signalling by the 70kd S6 protein kinases".
Food Chem. Toxicol., vol. 21, No. 6, 1983, pp. 779-783, XP000568648, R. G. Arora et al.: "Inhibition of ochratoxin A teratogenesis by zeraralenone and diethylstilbestrol".
Bennett et al, "Use of the Anabolic Agent Zearanol (Resorcylic Acid Lactone) as a Growth Promotor for Cattle," The Veterinary Record, 94:235-239 (1974).
Edwards et al, "Murine Macrophage Activation with Resorcyclic Acid Lactones (RALs): Comparison with Diethylstilbestrol and 17.beta.-Estradiol," Immunopharmacology, 17:107-118 (1989).
Gal et al, "Studies on the Biological Action of Malonitireiles: I. The Effect of Substituted Malononitriles on the Growth of Transplanted Tumors in Mice," Cancer Research, 12:565-573 (1952).
Katzenellenbogen et al, "Zearalenones: Characterization of the Estrongenic Potencies and Receptor Interactions of a Series of Fungal .beta.-Resorcyclic Acid Lactones," Endocrinology, 105:33-40 (1979).
Kuiper-Goodman et al, "Risk Assessment of the Mycotoxin Zearalenone," Regulatory Toxicology and Pharmacology, 7:253-306 (1987).
Mastri et al, "In Vivo Oestrogenicity and Binding Characteristics of .alpha.-Zearalanol (P-1496) to Different Classes of Oestrogen Binding Proteins in Rat Liver," J. Steroid Biochem., 23(3):279-289 (1985).
Roche et al, "Resorcylic Acid Lactone as an Anabolic Agent in Cattle," Veterinary Research Communications, 7:45-50 (1983).
Sheffield et al, "Zeranol (.beta.-Resorcyclic Acid Lactone), A Common Residous Component of Natural Foodstuffs, Stimulates Developmental Growth of the Mouse Mammary Gland," Cancer Letters, 28:77-83 (1985).
Willemart et al, "A Ral Compound as an Anabolic in Cattle," Veterinary Research Communications, 7:35-44 (1983).
Giese Neill A.
Lokker Nathalie
COR Therapeutics Inc.
Reamer James H.
LandOfFree
Method and compositions for inhibiting protein kinases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and compositions for inhibiting protein kinases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and compositions for inhibiting protein kinases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-958069